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tory concentration (MIC) distribution of moxifloxacin and levofloxacin in S. pneu-
moniae isolates remained stable during 2004-2009 and resistance to moxifloxacin
and levofloxacin was low (1%). Moxifloxacin was the most potent fluoroquinolone
available for treatment of S. pneumoniae infections in Belgium with MIC90 of 0.19
mg/L. CONCLUSIONS: The volume of fluoroquinolone use remains well controlled
and fluoroquinolones were primarily used in those indications where they have
been shown to yield clinical benefit. The use of fluoroquinolones has not led, to
date, to an increase in the rate of pneumococcal resistance to fluoroquinolones.
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OBJECTIVES: Chronic rhinosinusitis (CRS) is a debilitating chronic condition with
substantial burden of illness. The purpose of this study was to obtain information
to inform a budget impact model for balloon sinuplasty (BSP) in CRS in Asia Pacific
(Australia, China, India, Japan, South Korea). METHODS: Three systematic reviews
of the literature were undertaken (October 2010 – February 2011) using Medline,
Embase and Cochrane to identify prevalence of CRS in the region, clinical evidence
for BSP and economic evidence for CRS. Manual searching, including HTA data-
bases and interviews with clinicians in each country, supplemented the review.
RESULTS: A total of 171 epidemiological, 50 clinical and 95 economic articles were
identified. After title/abstract and full text review, 14 epidemiological, 14 clinical
and 6 economic articles remained. However, population-based prevalence of CRS
was only reported for Japan (0.05%) and Korea (1% to 7%), with the remainder of the
articles discussing risk factors or subcategories of the disease. Manual searching of
key country specific journals, published articles and guidelines, the internet (in-
cluding Mandarin search) and secondary data sources identified prevalence of CRS
for Australia (9%) and India (8%), but not China. Two comparative (non-ran-
domised) studies of BSP and nine case-series (n10 patients) were identified. BSP
was reported to be favourable in terms of safety and efficacy with high ostia pa-
tency, shorter recovery time, improved symptoms and patient satisfaction. Eco-
nomic studies confirmed the high economic burden of CRS. One economic study on
BSP was identified which, from a USA payer perspective, demonstrated lower cost
than conventional endoscopic sinus surgery predominantly due to the lower cost
of revision surgery and associated shorter surgical time. CONCLUSIONS: Tradi-
tional data sources provide limited information on prevalence of CRS in Asia-
Pacific. BSP appears to have value both clinically and economically, however fur-
ther research is required to accurately quantify these benefits.
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OBJECTIVES: To identify factors that affect smoking status in Greece.METHODS:A
strictly-structured questionnaire-based telephone survey was conducted to a sam-
ple of 6559 individuals, 18 years, representative of the Greek population and
stratified according to age, sex and place of residence. Participants were requested
to answer to questions, regarding, among others, smoking status, family/marital
status, self-reported quality-of-life, presence of a health problem, level of educa-
tion, family income and type of occupancy. The survey took place from January to
March 2011. A logistic regression analysis was conducted to identify the factors
that influence smoking status (non-smokers vs. smokers, ex- vs. current smokers).
RESULTS: Distinguishing between non-smokers vs. smokers, higher income (Odds
Ratio: 1.08, 95% Confidence Interval: 1.03-1.13), absence of a health problem (OR:
1.31, 95%CI: 1.14-1.50) and living single (ORs: 1.46, 1.18 and 2.25 for singles, widows/
widowers and divorcees, respectively) were associated with a greater risk of smok-
ing. Female gender, enhanced quality-of-life status, and higher levels of education
had a protective influence on the probability of smoking (ORs: 0.69, 0.79, 0.91).
Comparing ex- and current smokers, the regression showed that the probability of
quitting was associated with higher levels of education (OR: 0.91, 95%CI: 0.88-0.95),
increasing age (OR: 0.97, 95%CI: 0.95-0.97) and enhanced quality-of-life (OR: 0.88,
95%CI: 0.80-0.98), whereas, women (OR: 1.81, 95%CI: 1.46-2.24), people without
health-related problems (OR: 1.62, 95%CI: 1.32-1.99) and those with a higher income
(OR: 1.05, 95%CI: 1.01-1.13) had increased probability of being current smokers.
Pensioners and students were more likely to have quitted smoking than other
occupational groups. All reported values are statistically significant (p0.05).
CONCLUSIONS: Socioeconomic factors significantly influence smoking status and
the decision to quit. In Greece, as in other countries with a high prevalence of
smoking, evidence like the aforementioned can serve as important inputs in the
health policy decision-making process.
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OBJECTIVES: NHS Stop Smoking Services provide various options for support and
counselling. Most services have evolved to suit local needs without any retrospec-
tive evaluation of their efficiency. Objective was to describe the structure and out-
comes associated with different services. METHODS: Local service evaluations
were done in three primary Care Trusts (PCTs) by conducting standardised inter-
views with key personnel in addition to extraction and analysis of data from 400
clients accessing the service after 1st April 2008 in each PCT. RESULTS: The PCTs
varied in geography, population size and quit rate (47%-63%). Services were deliv-
ered by PCT-led specialist teams (PCT1), community-based health care providers
(PCT3) and a combination of the two (PCT2) with varying resources and interven-
tions in each. Group support resulted in the highest quit rates (64.3% for closed
groups v 42.6% for one-to-one support (PCT1)). Quit rates were higher for PCT (75%)
versus GP (60%) and pharmacist-delivered care (40%) where all existed in the same
model (PCT2). The most-prescribed therapy was NRT (56%-65%), followed by va-
renicline (25%-34%), counselling alone (6%-8%) and bupropion (2%-4%). Quit rates
for NRT at 4 weeks were 43%-55% across the 3 PCTs; 60% -81% for varenicline and
38%-91% for bupropion. CONCLUSIONS: The results suggest that service structure,
method of support, healthcare professional involved and pharmacotherapy all play
a role in a successful quit. Services must be tailored to support individual needs
with patient choice and access to varied services being key factors.
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OBJECTIVES: GETQUIT clinics (GQCs) are free, US-based, 1-hour workshops spon-
sored by Pfizer, and designed to support smokers planning to quit. The clinics are
hosted by physicians and tobacco-treatment specialists. We evaluated the impact
of the GQCs on attendees’ knowledge around developing a quit plan, readiness to
change, and intent-to-act regarding smoking cessation. METHODS: Subjects pre-
enrolled at GQCs between March-November 2010 were invited to a pre-clinic tele-
phone interview and, within 7 days of attendance, to a post-clinic telephone inter-
view. A survey was administered at both interviews to compare changes in
responses. Incentives were offered to subjects completing both interviews. Change
in subject knowledge was assessed by comparing pre- vs. post-clinic level of agree-
ment with seven statements on developing a quit plan. Readiness-to-change was
based on the proportion of subjects progressing 1 stage on the Transtheoretical
Model Stages of Change-Short Form. Intent to act was assessed post-clinic only.
Subject demographics, smoking history and nicotine dependence were also
obtained. RESULTS: Of 3147 persons contacted, 369 completed both interviews.
Mean age was 51.4y, 69% were female. All knowledge endpoints showed significant
improvement post-clinic (p0.0001 for all). Although there was no significant im-
provement in readiness-to-change overall, there were larger improvements among
those in earlier stages of change pre-clinic (Contemplators 25% improvement vs.
Preparation 5%). Post-clinic, 38% of attendees had contacted their doctor about
quitting smoking and 44% of the remainder intended to do so within the next 2
weeks. Approximately 90% agreed or strongly agreed that they viewed their health
care provider as a partner in managing their overall health since attending the
GETQUIT clinic.CONCLUSIONS: Effecting successful behavior change requires sus-
tained effort and multiple techniques. The GQCs, although brief, significantly im-
proved attendees’ knowledge on how to quit successfully. Additionally, more than
a third of attendees reported engaging with their doctors about quitting after at-
tending.
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OBJECTIVES: To estimate the economic consequences of an ameliorated adher-
ence to GOLD guidelines recommendations for Chronic Obstructive Pulmonary
Disease (COPD) management in the Italian clinical practice. METHODS: A Markov
model compares the current approach for COPD treatment (CURRENT strategy)
with a strategy of care (GOLD GL strategy) mainly consisting of universal spirome-
try-based staging, alignment of the pharmacological therapy to guideline recom-
mendations implemented by expert opinion. Drug consumption of the CURRENT
strategy is based on data of 3113 patients collected by three Local Health Units. The
consumption of other health resources, i.e. medical visits and inpatient care, is
estimated from a multicentre observational Italian study, from which also their
variation as a consequence of the improved adherence to GOLD is derived. Costs
are calculated from the National Health Service perspective, based on published
analyses and current prices and tariffs. RESULTS: The adoption of the GOLD GL
strategy for the treatment of the over 1250,000 prevalent Italian COPD patients
results in a cost increase of 19 million Euros for the restaging and of 100 million
Euros for the redefinition of the clinical management strategy, compared to the
CURRENT strategy. Furthermore, the adaptation of the pharmacological therapy to
GOLD recommendations, (essentially a higher usage of long-acting beta agonist/
corticosteroid combinations), increases costs by more than 320 million Euros. On
the other side, the consumption of other health care resources is reduced by 44%,
an estimated cost saving of more than 850 million Euros. The net cost saving
associated with the improved GOLD guideline adoption results in 410 million Euros.
CONCLUSIONS: The model estimates that the adoption of GOLD guidelines in the
Italian clinical practice is associated to an increase of expenses for pharmaceuti-
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